COMMUNIQUÉS West-GlobeNewswire

Valitor to Participate in the 2026 RBC Capital Markets Global Healthcare Conference
13/05/2026
BERKELEY, Calif., May 13, 2026 (GLOBE NEWSWIRE) -- Valitor, a biotechnology company engineering a new generation of ophthalmic medicines, today announced that chief executive officer Gregory D. Kunst will share a [...]
Silexion Therapeutics Announces Initiation of GMP Clinical Supply Manufacturing of SIL204 with Leading Global CDMO, and New Approval of Phase 2/3 Trial From Tel Aviv Sourasky Medical Center
13/05/2026
Silexion advances toward Phase 2/3 trial in KRAS-driven pancreatic cancer, as SIL204 begins GMP clinical manufacturing in collaboration with global leading manufacturing partner Catalent at its European center of [...]
SS Innovations Reports First Quarter 2026 Financial Results
13/05/2026
Record quarterly revenue driven by strong growth in SSi Mantra installations and procedures FORT LAUDERDALE, Fla., May 13, 2026 (GLOBE NEWSWIRE) -- SS Innovations International, Inc. (the “Company” or “SS Innovations [...]
Palvella Therapeutics Announces Uplisting to the Nasdaq Global Market
13/05/2026
Uplisting reflects Palvella’s continued progress advancing potential first-in-disease therapies for serious, rare skin diseases and vascular malformations WAYNE, Pa., May 13, 2026 (GLOBE NEWSWIRE) -- Palvella [...]
BrainsWay Reports First Quarter 2026 Financial Results and Operational Highlights
13/05/2026
R evenue grew approximately 35 % y ear- o ver- y ear to $1 5 .5 million for Q1 2026 Net income increased by over 100 % year-over-year to $ 2. 3 million for Q1 2026 Adjusted EBITDA for Q1 of 2026 more than doubled year- [...]
Protara Therapeutics Announces First Quarter 2026 Financial Results and Provides a Business Update
13/05/2026
The Company intends to submit a Biologics License Application (BLA) for TARA-002 in Lymphatic Malformations (LMs) in 2H 2027 Hosting virtual investor webinar discussing LMs program with key opinion leader (KOL) [...]
Century Therapeutics Reports First Quarter Financial Results and Business Updates
13/05/2026
CNTY-813, Century’s type 1 diabetes iPSC-derived islet therapy with functional-cure potential, remains on track for IND in 4Q 2026; initial clinical data expected in 2H 2027 Upcoming oral presentation at the American [...]
HepaRegeniX to Present Interim Phase 1b Data for Darizmetinib (HRX215) in a Late-Breaking Oral Presentation at the European Association for the Study of the Liver (EASL) Congress 2026
13/05/2026
Tuebingen , Germany, May 13 , 202 6 – HepaRegeniX GmbH (“HepaRegeniX”), a clinical-stage biotech company advancing novel therapies for acute and chronic liver diseases, announces that its abstract highlighting clinical [...]
Anaveon Appoints Thomas P. Mathers as Chair of the Board of Directors
13/05/2026
BASEL, Switzerland, May 13, 2026 (GLOBE NEWSWIRE) -- Anaveon, a late-stage biotechnology company pioneering precision biologics to reprogram the immune system for the treatment of autoimmune and inflammatory diseases, [...]
Bavarian Nordic Announces Interim Results for the First Three Months of 2026
13/05/2026
COPENHAGEN, Denmark, May 13, 2026 – Bavarian Nordic A/S (OMX: BAVA) announced today its interim financial results and business progress for the first three months of 2026. Revenue for the first three months was DKK 1, [...]
Valneva Reports First Quarter 2026 Financial Results and Provides Corporate Updates
13/05/2026
Total product sales of €30.5 million Cash position of €105.3 million as of end March 2026, excluding proceeds from successful reserved offering completed in April 2026 1 Program launched in April to further reduce [...]
IBA lance AdaPTinsight XR, la nouvelle génération d’imagerie CBCT pour la protonthérapie guidée par l’image
13/05/2026
Une solution d’imagerie CBCT pour les systèmes de protonthérapie Proteus ® offrant une visibilité claire qui permet des traitements IGPT en toute confiance Louvain-la-Neuve, Belgique, le 13 mai 2026 – IBA (Ion Beam [...]
Aligos Therapeutics Announces Ten Abstracts Accepted for Presentation at the EASL Congress 2026
13/05/2026
SOUTH SAN FRANCISCO, Calif., May 13, 2026 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on improving patient outcomes through best-in-class therapies [...]
Assembly Biosciences to Present Topline Phase 1a Data on Hepatitis Delta Virus Entry Inhibitor ABI-6250 at the EASL Congress 2026
13/05/2026
SOUTH SAN FRANCISCO, Calif., May 13, 2026 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a biotechnology company developing innovative therapeutics targeting serious viral diseases, today announced [...]
IBA introduces AdaPTinsight XR, the next generation of CBCT imaging for image-guided proton therapy
13/05/2026
Proton therapy CBCT imaging solution across Proteus ® Portfolio providing clarity and confidence in IGPT Louvain-la-Neuve, Belgium, May 13, 2026 – IBA (Ion Beam Applications S.A., EURONEXT), the world leader in particle [...]
Fangzhou Showcases “AI+H2H” Chronic Disease Service Innovations at the National Intelligent Medicine Conference
13/05/2026
WUHAN, China, May 13, 2026 (GLOBE NEWSWIRE) -- Fangzhou Inc. (“Fangzhou” or the “Company”) (HKEX: 06086), a leading provider of AI‑driven Internet healthcare solutions, participated in the 2026 National Medical Industry [...]
Wegovy® pill delivered 21.6% weight loss in early responders and doubled mobility improvement, according to new Novo Nordisk data at ECO2026
13/05/2026
Almost a third of adults taking Wegovy ® pill (oral semaglutide 25 mg) were early responders to treatment, achieving an average of 13.2% weight loss after four months and 21.6% weight loss at the end of the OASIS 4 [...]
Valneva publie ses résultats financiers audités et consolidés pour le premier trimestre 2026
13/05/2026
Ventes de produits de 30,5 millions d’euros Position de trésorerie de 105,3 millions d’euros à fin mars 2026, hors produit de la levée de fonds réservée réalisée avec succès en avril 2026 1 Lancement, en avril 2026, d’ [...]
Inventiva to Present Abstracts at the EASL Congress 2026
13/05/2026
Daix (France), New York City (New York, United States) , May 13, 2026 – Inventiva (Euronext Paris and NASDAQ: IVA ) (“Inventiva” or the “Company”), a clinical-stage biopharmaceutical company focused on the development [...]

Pages